Trial Profile
A biomarker study as predictive indicators of nivolumab efficacy by using neutrophil-to-lymphocyte ratio and lymphocyte-to-monocyte ratio in patients with metastatic non-small cell lung cancer.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 22 Jun 2018
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Non-small cell lung cancer
- Focus Biomarker; Pharmacodynamics; Therapeutic Use
- 22 Jun 2018 New trial record
- 05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology